Antisense oligonucleotides therapy - MAHZI Therapeutics
Latest Information Update: 27 Mar 2024
At a glance
- Originator MAHZI Therapeutics
- Class Antisense oligonucleotides
- Mechanism of Action CHD2 protein expression stimulants; Gene silencing
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Neurodevelopmental disorders
Most Recent Events
- 22 Mar 2024 Preclinical trials in Neurodevelopmental disorders in USA (Parenteral) (MAHZI Therapeutics pipeline, March 2024)